Your session is about to expire
Oxybutynin vs Toviaz
Introduction
For patients with overactive bladder (OAB) disorder or other types of urinary incontinence, certain medications that alter the signaling of nerves in the bladder can help to stabilize and manage symptoms. Oxybutynin and Toviaz are two such drugs commonly prescribed for this condition. Both work by blocking the action of acetylcholine, a neurotransmitter which can increase urinary urgency, but they do so through different mechanisms. Oxybutynin is classified as an antimuscarinic agent that works primarily on M2 and M3 subtypes of muscarinic receptors located in the detrusor muscle of the bladder wall. On the other hand, Toviaz (Fesoterodine) is also an antimuscarinic medication but it's metabolized into its active form 5-hydroxymethyl tolterodine which has high specificity for M3 receptors, considered to be largely responsible for bladder contractions.
Oxybutynin vs Toviaz Side By Side
| Attribute | Ditropan | Toviaz |
|---|---|---|
| Brand Name | Ditropan | Toviaz |
| Contraindications | Glaucoma, kidney disease, liver disease, certain heart conditions | Glaucoma, kidney disease, liver disease, certain heart conditions |
| Cost | $100 to $150 for 60 tablets of 5 mg | $200 to $250 for 30 capsules of 4mg |
| Generic Name | Oxybutynin | Fesoterodine |
| Most Serious Side Effect | Difficulty breathing or swallowing, swelling of the face, lips, tongue or throat, hives or severe skin reactions, blurred vision or difficulty focusing, rapid heart rate, palpitations, light-headedness, confusion with high body temperature, severe nervous system symptoms, symptoms indicating electrolyte imbalance | Signs of an allergic reaction, severe skin reaction, angioedema, difficulty swallowing, changes in vision, rapid or irregular heartbeats, confusion and unusual behavior changes |
| Severe Drug Interactions | Certain antifungal drugs (like itraconazole) or antibiotics (such as erythromycin) | Certain antifungal drugs (like itraconazole) or antibiotics (such as erythromycin) |
| Typical Dose | 5–20 mg/day | 4 mg per day, can be increased to 8 mg/day |
What is Oxybutynin?
Oxybutynin (the generic name for Ditropan) is an anticholinergic medication primarily used to treat symptoms of overactive bladder. It was first approved by the FDA in 1975 and works by relaxing the bladder muscles, effectively reducing urinary urgency, frequency, and incontinence episodes. Oxybutynin is available as a tablet or patch and has been widely prescribed due to its efficacy.
On the other hand, Toviaz (generic name Fesoterodine) is another anticholinergic drug also indicated for overactive bladder symptoms treatment. Approved by the FDA in 2008, it functions similarly to Oxybutynin but may potentially offer better tolerability with fewer side effects like dry mouth or constipation which are common with this class of drugs.
Although both medications work on similar pathways affecting urinary function regulation, they differ slightly when it comes to their influence on certain neurotransmitters and subsequent possible side effects profile. Your choice between them should be made after considering these differences alongside your doctor's guidance.
What conditions is Oxybutynin approved to treat?
Oxybutynin is approved for the treatment of several urinary conditions:
- Overactive bladder symptoms, such as a strong need to urinate with leaking or wetting accidents (urge urinary incontinence), a strong need to urinate right away (urgency), and frequent urination (frequency)
- Pediatric voiding dysfunction
- Neurogenic bladder disorders
On the other hand, Toviaz is specifically approved for:
- Managing overactive bladder symptoms including urgency, frequency and urge incontinence.
How does Oxybutynin help with these illnesses?
Oxybutynin aids in managing overactive bladder by blocking the action of acetylcholine, a neurotransmitter that sends signals to your brain that trigger the need for urination. It does this by binding to the muscarinic receptors located on the smooth muscle of the bladder, thus inhibiting contractions and increasing its storage capacity. Acetylcholine is a chemical messenger in both the central and peripheral nervous systems, playing crucial roles in various bodily functions including heart rate, digestion, respiratory rate and salivation among others. People with an overactive bladder have hypersensitive responses due to excessive amounts of acetylcholine causing frequent urges for urination or involuntary loss of urine (incontinence). By decreasing these excitatory signals through blocking acetylcholine's effects via oxybutynin use, patients can gain better control over their urinary frequency and urgency.
What is Toviaz?
Toviaz is a brand name for fesoterodine, which is a muscarinic receptor antagonist. This means it blocks the action of acetylcholine, a neurotransmitter, on muscarinic receptors in the bladder to prevent involuntary contractions and reduce urinary frequency and urgency. Toviaz was first approved by the FDA in 2008. Because fesoterodine does not act on serotonin receptors like SSRI antidepressants do, it has different side effects than drugs such as Prozac. In particular, Toviaz does not cause sedation or weight gain; however common side effects can include dry mouth and constipation due to its antimuscarinic properties. The effects of blocking acetylcholine can be beneficial for treating overactive bladder symptoms especially in patients who do not respond well to other treatments.
What conditions is Toviaz approved to treat?
Toviaz (fesoterodine) is a medication that has been approved by the FDA for managing symptoms of overactive bladder, including:
- Urgency: a strong and sudden desire to urinate
- Frequency: needing to urinate often
- Urge incontinence: leakage or wetting accidents due to an urgent need to pass urine.
How does Toviaz help with these illnesses?
Fesoterodine, the active ingredient in Toviaz, works by blocking muscarinic receptors in the body which helps to control bladder muscle contractions and thus manages symptoms of an overactive bladder such as frequent urination or urgency. As an antimuscarinic agent it is highly selective for M3 receptors found predominantly in the urinary tract. This specificity makes Toviaz effective at relieving symptoms while causing fewer side effects than less selective medications like oxybutynin. In addition, its extended-release formulation allows for once-daily dosing which can improve patient compliance compared to multiple daily doses required with many other medications including oxybutynin.
How effective are both Oxybutynin and Toviaz?
Both oxybutynin and fesoterodine (Toviaz) have been proven effective in managing symptoms of overactive bladder, with their approval by the FDA separated only by a few decades. Since they act on different types of receptors in the body, they may be prescribed under different circumstances. The effectiveness of oxybutynin and Toviaz in alleviating urinary urgency was directly studied in a double-blind clinical trial; both drugs demonstrated similar efficacy in treating symptoms as well as similar safety profiles.
A 2003 review showed that immediate-release oxybutynin is effective from the first week of treatment for reducing episodes of urinary urgency and frequency, along with a favorable side effect profile compared to older antimuscarinic agents. It has since become one of the most widely-prescribed drugs for overactive bladder globally. Oxybutynin was one of the first anticholinergic medications developed specifically for this condition, so there is significant research backing its effectiveness.
Meanwhile, a 2012 meta-analysis indicated Toviaz seems more effective than placebo at improving urge continence and total daily micturitions; it also appears to have comparable efficacy to other common treatments for overactive bladder. However, like bupropion mentioned earlier, Toviaz might be considered after other first-line treatments due to cost considerations or individual patient characteristics. Although data confirming its overall superiority is still lacking compared to established options like oxybutynin, thanks to its unique pharmacology - including selective activity at M3 muscarinic receptors - Toviaz may be an optimal choice for patients who didn't respond well or experienced bothersome side effects with other anticholinergics.
Related trials for oxybutynin and toviaz
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Oxybutynin typically prescribed?
Oral dosages of Oxybutynin range from 5–20 mg/day, but studies have indicated that 5 mg/day is sufficient for most people in treating overactive bladder. This dosage can be increased after a few weeks if there is no response, with the maximum dosage not exceeding 20 mg/day. On the other hand, Toviaz (fesoterodine) comes as an extended-release tablet and is generally taken once a day at a dose of 4-8mg. For most patients with overactive bladder symptoms, starting on 4mg per day is typically effective. If necessary and well-tolerated by the patient, this may be increased to 8mg per day after one week or longer.
At what dose is Toviaz typically prescribed?
Toviaz treatment is typically initiated at a dosage of 4 mg per day. If necessary, the dose can then be increased to 8 mg/day, taken as one single daily dose. The maximum prescribed dose is 8 mg/day, which may be considered if there is no significant response to the initial treatment after a week or two. It's important that Toviaz should not exceed this maximum limit due to potential increase in side effects. Always make sure you take your medication as directed by your healthcare provider and consult them before making any changes to your regimen.
What are the most common side effects for Oxybutynin?
Common side effects of Oxybutynin may include:
- Dry mouth
- Dizziness, drowsiness (somnolence)
- Blurred vision
- Nausea and vomiting
- Constipation or diarrhea
- Abdominal pain (discomfort in the digestive tract)
- Heat intolerance and decreased sweating
- Insomnia
- Weakness (asthenia)
On the other hand, Toviaz is likely to cause:
- Dry mouth
- Constipation
- Urinary tract infection
- Indigestion or heartburn (dyspepsia)
- A dry throat or eyes.
It's important to note that not everyone will experience these side effects. If you have any concerns about potential side effects, please consult with your healthcare provider.
Are there any potential serious side effects for Oxybutynin?
The potential side effects of Oxybutynin can be serious and include:
- Difficulty breathing or swallowing, which could indicate an allergic reaction
- Swelling of the face, lips, tongue or throat
- Hives or severe skin reactions including redness, itching, pain and rash
- Blurred vision or difficulty focusing; dilated pupils
- Rapid heart rate (tachycardia), palpitations in your chest and light-headedness that may lead to fainting
- Changes in mental status such as confusion associated with high body temperature (fever) and flushed skin; possible heat stroke due to reduced sweating -Severe nervous system symptoms - rigid muscles, fever, sweating, fast or uneven heartbeat patterns. These symptoms might suggest a condition called Neuroleptic Malignant Syndrome.
- Symptoms indicating electrolyte imbalance: headaches, feeling confused/disoriented/weak/dizzy/unsteady on feet; these might happen if Oxybutynin is causing decreased levels of sodium in your body.
If you experience any of these adverse effects while taking Oxybutynin it's critical that you seek immediate medical attention.
What are the most common side effects for Toviaz?
Toviaz, also known as Fesoterodine, is another medication used for overactive bladder. Potential side effects of Toviaz may include:
- Dry mouth or throat
- Constipation and stomach upset
- Blurred vision
- Sleep disturbances, such as insomnia
- Headache and dizziness
- Fast heartbeat in some cases -Increased risk of heatstroke because it decreases sweating
It's also crucial to note that while these side effects can occur, they are not always guaranteed. Each patient reacts differently to medication and should consult with their healthcare provider if any adverse reactions occur.
Are there any potential serious side effects for Toviaz?
In rare instances, Toviaz (fesoterodine) can cause serious side effects. If you experience any of the following symptoms while taking Toviaz, consult your doctor immediately:
- Signs of an allergic reaction: hives; difficulty breathing; swelling in your face or throat
- Symptoms indicating a severe skin reaction: fever, sore throat, burning sensations in the eyes, skin pain followed by a red or purple rash that spreads and leads to blistering and peeling
- Indications of angioedema: swelling of the hands, feet, ankles or lower legs; swollen lymph glands
- Difficulty swallowing
- Changes in vision such as blurred vision or seeing halos around lights
- Rapid heartbeat/ irregular heartbeats
- Confusion and unusual behavior changes
These are not all possible side effects but are among those more likely to require immediate medical attention.
Contraindications for Oxybutynin and Toviaz?
Both Oxybutynin and Toviaz, along with most other bladder control medications, may cause an increase in some symptoms for certain individuals. If you notice your symptoms worsening or any unusual side effects such as hallucinations, severe dizziness, irregular heartbeat or trouble breathing, please seek immediate medical attention.
Neither Oxybutynin nor Toviaz should be taken if you are currently taking or have recently taken certain antifungal drugs (like itraconazole) or antibiotics (such as erythromycin). Always inform your healthcare provider about all the medications you're using; these particular agents might require a period of clearance from your system to prevent potentially dangerous interactions with both Oxybutynin and Toviaz. Additionally, those with glaucoma, kidney disease, liver disease and certain heart conditions should use these medications under careful monitoring.
How much do Oxybutynin and Toviaz cost?
For the brand name versions of these drugs:
- The price for 60 tablets of Ditropan (oxybutynin, 5 mg) averages around $100 to $150, which works out to about $1.67–$2.50/day depending on your dose.
- The cost for a pack of 30 capsules Toviaz (fesoterodine fumarate, 4mg) is roughly between $200 and $250, working out to approximately $6.67-$8.33/day.
Thus if you are in the higher dosage range for oxybutynin (i.e., 15 mg per day or higher), then brand-name Toviaz could be less expensive on a per-day treatment basis. Please note that cost should not be a primary consideration in determining which drug is right for you.
As with many medications generic versions can provide significant savings:
- Oxybutynin (5 mg tablets) comes in packs of at least 30 tablets with costs ranging from about $.20 - $.70 per tablet depending on volume purchased and pharmacy used.
- Fesoterodine fumarate is available in packs from as low as just over one dollar up to three dollars per pill when larger quantities are purchased upfront.
These prices may vary based upon location, insurance coverage and other factors so it's always good practice to inquire locally before making decisions based solely on web-based pricing information.
Popularity of Oxybutynin and Toviaz
Oxybutynin, available under brand names such as Ditropan and Oxytrol, was estimated to have been prescribed to about 2.3 million people in the US in 2020. Oxybutynin accounted for around 30% of anticholinergic prescriptions used in bladder disorders treatment. This particular drug has a long history of use since its approval by the FDA back in the early '70s.
Fesoterodine Fumarate, more commonly known by its brand name Toviaz, is another medication often used to treat urinary issues like overactive bladder with symptoms of urgency, frequency, and leakage. It was prescribed to an estimated half a million people within the US during 2020. Fesoterodine accounts for approximately 8% of overall antimuscarinic prescriptions for overactive bladder (OAB). Its prevalence has generally been stable over the last decade.
Both medications are intended to alleviate similar symptoms; however they each come with their unique side effects profile which could weigh into patients' preference between these two options.
Conclusion
Both oxybutynin and Toviaz (fesoterodine) have established records of usage in managing symptoms of overactive bladder, and are supported by numerous clinical studies indicating that they are more effective than placebo treatments. There is potential for these medications to be used together under strict medical supervision due to their different mechanisms of action; however, this would also increase the risk of certain side effects.
Oxybutynin acts primarily as a muscle relaxant on the detrusor muscles of the bladder whereas fesoterodine works chiefly by blocking nerve signals that induce urinary urgency. Oxybutynin is frequently considered a first-line treatment option while Toviaz generally comes into consideration if patients fail to respond well to initial therapies or need additional symptom control.
Both drugs are available in generic forms which can lead to significant cost savings especially for patients who must pay out-of-pocket. It's worth noting that both oxybutynin and Toviaz may require an adjustment period - meaning the full benefits may not be immediately apparent.
The side effect profile is similar between these two drugs, with common complaints including dry mouth, constipation, blurred vision and cognitive issues. However, these side effects are often dose-dependent and can be managed effectively under a doctor’s care. For both medications, it's crucial for patients to report any unusual symptoms or problems promptly so adjustments can be made accordingly.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Jirschele, K., & Sand, P. K. (2012, September 14). Oxybutynin: past, present, and future. International Urogynecology Journal. Springer Science and Business Media LLC.http://doi.org/10.1007/s00192-012-1915-8
- Tzefos, M., Dolder, C., & Olin, J. L. (2009, November 17). Formulary Forum: Fesoterodine for the Treatment of Overactive Bladder. Annals of Pharmacotherapy. SAGE Publications.http://doi.org/10.1345/aph.1m308
- Altan‐Yaycioglu, R., Yaycioglu, O., Aydin Akova, Y., Guvel, S., & Ozkardes, H. (2005, March 2). Ocular side‐effects of tolterodine and oxybutynin, a single‐blind prospective randomized trial. British Journal of Clinical Pharmacology. Wiley.http://doi.org/10.1111/j.1365-2125.2005.02356.x
- Scheife, R., & Takeda, M. (2005, February). Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clinical Therapeutics. Elsevier BV.http://doi.org/10.1016/j.clinthera.2005.02.014
- Lucente. (2011, April). Development of oxybutynin chloride topical gel for overactive bladder. Open Access Journal of Urology. Informa UK Limited.http://doi.org/10.2147/oaju.s17046
- OKI, T., KIMURA, R., SAITO, M., MIYAGAWA, I., & YAMADA, S. (2004, November). Demonstration Of Bladder Selective Muscarinic Receptor Binding By Intravesical Oxybutynin To Treat Overactive Bladder. Journal of Urology. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/01.ju.0000138472.16876.8d
- Mansfield, K. (2009, December). Role of fesoterodine in the treatment of overactive bladder. Research and Reports in Urology. Informa UK Limited.http://doi.org/10.2147/rru.s5171
- Diokno, A. C., Appell, R. A., Sand, P. K., Dmochowski, R. R., Gburek, B. M., Klimberg, I. W., & Kell, S. H. (2003, June). Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trial. Mayo Clinic Proceedings. Elsevier BV.http://doi.org/10.4065/78.6.687
- Brand, S., Ghaleiha, Jahangard, Sherafat, Ahmadpanah, Holsboer-Trachsler, E., … Haghighi. (2012, September). Oxybutynin reduces sweating in depressed patients treated with sertraline: a double-blind, placebo-controlled, clinical study. Neuropsychiatric Disease and Treatment. Informa UK Limited.http://doi.org/10.2147/ndt.s36329
- Bolge, S. C., McDonnell, D. D., Chen, A., & Wan, G. J. (2007, July 3). Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. Current Medical Research and Opinion. Informa Healthcare.http://doi.org/10.1185/030079907x210598
- Schröder, A., & Thüroff, J. W. (2010, July). New strategies for medical management of overactive bladder in children. Current Opinion in Urology. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/mou.0b013e32833aa185
- Bang, L. M., Easthope, S. E., & Perry, C. M. (2003). Transdermal Oxybutynin. Drugs & Aging. Springer Science and Business Media LLC.http://doi.org/10.2165/00002512-200320110-00007